Quadrature Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Quadrature Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,123	Closed	-$707K	–	1837
2026 Q1	$707K	Buy	+35,123	New	+$566K	0.01%	676
2025 Q3	–	Sell	-19,973	Closed	-$226K	–	1274
2025 Q2	$226K	Buy	+19,973	New	+$244K	﹤0.01%	780

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Quadrature Capital's KALV Position: Q2 2026 in Review

Quadrature Capital sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 35,123 shares — an estimated $707K sold.

Quadrature Capital first reported a position in KALV in Q2 2025 and held it in 2 quarters. The position peaked at $707K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Quadrature Capital reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Quadrature Capital sold 35,123 KalVista Pharmaceuticals shares in Q2 2026, an estimated $707K.
Quadrature Capital first reported a position in KalVista Pharmaceuticals in Q2 2025 and held it in 2 quarters.
Quadrature Capital's KalVista Pharmaceuticals position peaked at $707K in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.